Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on April 6, 2005
Journal of the American Society of Nephrology
© 2005 American Society of Nephrology
doi: 10.1681/ASN.2004040275
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
ASN.2004040275v1
16/6/1788    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Slinin, Y.
Right arrow Articles by Collins, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Slinin, Y.
Right arrow Articles by Collins, A. J.

CLINICAL SCIENCE: Epidemiology and Outcomes

Calcium, Phosphorus, Parathyroid Hormone, and Cardiovascular Disease in Hemodialysis Patients: The USRDS Waves 1, 3, and 4 Study

Yelena Slinin 1, Robert N. Foley 2*, Allan J. Collins 2

1

*United States Renal Data System Coordinating Center


2

*United States Renal Data System Coordinating Center; and {dagger}University of Minnesota, Minneapolis, Minnesota


* To whom correspondence should be addressed. E-mail: rfoley{at}usrds.org.


  Abstract

Animal studies suggest that calcium-phosphorus homeostatic abnormalities cause cardiovascular disease in uremia; few observational studies in humans have explored this. Associations in the retrospective United States Renal Data System Waves 1, 3, and 4 Study of 14,829 patients who were on hemodialysis on December 31, 1993, were examined. Mean age and duration of renal replacement therapy were 60.0 and 3.2 yr, respectively; 40.7% had diabetes. Quintiles (Q1 to Q5) of (albumin-adjusted) calcium were ≤8.7, 8.8 to 9.2, 9.3 to 9.6, 9.7 to 10.2, and >10.2 mg/dl; phosphorus, ≤4.4, 4.5 to 5.3, 5.4 to 6.3, 6.4 to 7.5, and >7.5 mg/dl; calcium-phosphorus product, ≤40.9, 41.0 to 50.1, 50.2 to 59.2, 59.3 to 71.0, and >71.0 mg2/dl2; and parathyroid hormone (PTH), ≤37, 38 to 99, 100 to 210, 211 to 480, and >480 pg/ml. Higher calcium levels were associated with fatal or nonfatal cardiovascular events (adjusted hazards ratio, 1.08 for Q5, versus Q1) and all-cause mortality (Q2, 1.07; Q4, 1.11; Q5, 1.14). Phosphorus levels were associated with cardiovascular events (Q2, 1.06; Q3, 1.13; Q4, 1.14; Q5, 1.25) and mortality (Q4, 1.10; Q5, 1.19), calcium-phosphorus product was associated with cardiovascular events (Q3, 1.09; Q4, 1.14; Q5, 1.24) and mortality (Q4, 1.09; Q5, 1.19), and PTH levels were associated with cardiovascular events (Q5, 1.12) and mortality (Q5, 1.17). Despite limitations (including retrospective design; noncurrent study era; and lack of serial calcium, phosphorus, and PTH measurements), this study suggests that disorders of calcium homeostasis are associated with fatal and nonfatal cardiovascular events and all-cause mortality in hemodialysis patients.


This article has been cited by other articles:


Home page
 CJASNHome page
M. Ketteler, M. Rix, S. Fan, N. Pritchard, O. Oestergaard, S. Chasan-Taber, J. Heaton, A. Duggal, and P. A. Kalra
Efficacy and Tolerability of Sevelamer Carbonate in Hyperphosphatemic Patients Who Have Chronic Kidney Disease and Are Not on Dialysis
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1125 - 1130.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
P. P. How, D. L. Mason, and A. H. Lau
Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder
Journal of Pharmacy Practice, June 1, 2008; 21(3): 196 - 213.
[Abstract] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Mathew, K. S. Tustison, T. Sugatani, L. R. Chaudhary, L. Rifas, and K. A. Hruska
The Mechanism of Phosphorus as a Cardiovascular Risk Factor in CKD
J. Am. Soc. Nephrol., June 1, 2008; 19(6): 1092 - 1105.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. L. Melamed, J. A. Eustace, L. C. Plantinga, B. G. Jaar, N. E. Fink, R. S. Parekh, J. Coresh, Z. Yang, T. Cantor, and N. R. Powe
Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study
Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1650 - 1658.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
K. Yamada and S. Fujimoto
Reply
Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1457 - 1458.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
L. Gnudi
Serum intact parathyroid hormone in diabetic patients on haemodialysis: what is the treatment goal?
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 24 - 26.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. Coen, M. Manni, D. Mantella, A. Pierantozzi, A. Balducci, S. Condo, S. DiGiulio, L. Yancovic, B. Lippi, S. Manca, et al.
Are PTH serum levels predictive of coronary calcifications in haemodialysis patients?
Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3262 - 3267.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. A. Ray, W. J. Valentine, and A. J. Palmer
Cost utility analysis of cinacalcet in addition to standard of care in the UK
Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3355 - 3357.
[Full Text] [PDF]

Home page
 CJASNHome page
G. M. Chertow, L. B. Pupim, G. A. Block, R. Correa-Rotter, T. B. Drueke, J. Floege, W. G. Goodman, G. M. London, K. W. Mahaffey, S. M. Moe, et al.
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and Design Overview
Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 898 - 905.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. M. Brunelli and S. Goldfarb
Hypophosphatemia: Clinical Consequences and Management
J. Am. Soc. Nephrol., July 1, 2007; 18(7): 1999 - 2003.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
R. N. Foley
Phosphorus Comes of Age as a Cardiovascular Risk Factor
Arch Intern Med, May 14, 2007; 167(9): 873 - 874.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
F. Koiwa, T. Kakuta, R. Tanaka, and S. Yumita
Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism
Nephrol. Dial. Transplant., February 1, 2007; 22(2): 522 - 528.
[Abstract] [Full Text] [PDF]

Home page
 Annals of Clinical & Laboratory ScienceHome page
A. A. Fisher, E. K. Southcott, W. Srikusalanukul, M. W. Davis, P. E. Hickman, J. M. Potter, and P. N. Smith
Relationships between Myocardial Injury, All-cause Mortality, Vitamin D, PTH, and Biochemical Bone Turnover Markers in Older Patients with Hip Fractures
Ann. Clin. Lab. Sci., January 1, 2007; 37(3): 222 - 232.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
S. M. Moe and G. M. Chertow
The Case against Calcium-Based Phosphate Binders
Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 697 - 703.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
G. M. Chertow, S. Blumenthal, S. Turner, M. Roppolo, L. Stern, E. M. Chi, J. Reed, and on behalf of the CONTROL Investigators
Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium x Phosphate
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 305 - 312.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
K. Jindal, C. T. Chan, C. Deziel, D. Hirsch, S. D. Soroka, M. Tonelli, and B. F. Culleton
CHAPTER 3: Mineral Metabolism
J. Am. Soc. Nephrol., March 1, 2006; 17(3_suppl_1): S11 - S15.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. Jean, C. Chazot, and B. Charra
Hyperphosphataemia and related mortality
Nephrol. Dial. Transplant., February 1, 2006; 21(2): 273 - 280.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
W. M. McClellan and G. M. Chertow
Beyond Framingham: Cardiovascular Risk Profiling in ESRD
J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1539 - 1541.
[Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673